Regeneron Pharmaceuticals, Inc. (BVMF:REGN34)

Market Cap	392.95B
Revenue (ttm)	75.93B
Net Income (ttm)	24.40B
Shares Out	n/a
EPS (ttm)	221.67
PE Ratio	16.11
Forward PE	15.74
Dividend	0.22 (0.33%)
Ex-Dividend Date	Nov 18, 2025

Volume	20
Average Volume	943
Open	65.81
Previous Close	67.28
Day's Range	65.81 - 66.00
52-Week Range	44.82 - 80.02
Beta	0.39
RSI	54.83
Earnings Date	Feb 3, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 15,106
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: REGN34

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD